Epigenetic Proteins

Epigenetics, an increasingly popular field of drug discovery,is the study of heritable changes in gene expression that occur without changes in the DNA sequence. The epigenome is considered to be in constant flux and is responsive to environmental and pharmaceutically active molecules. Epigenetics-related enzymes and proteins catalyze the addition or removal of an array of covalent modifications on histone and non-histone proteins. For these reasons, epigenetics is becoming an increasingly important realm for drug therapies. Indeed, several drugs directed towards epigenetic modifying enzymes are already on the market with more in the clinic to treat cancer.

Readers, Writers and Erasers used in the Epigenetic Screening and Profiling Service from Eurofins Pharma Discovery Service are now available for direct purchase.  Since 2012 pharmaceutical clients have received high-quality and reproducible results with these in-house manufactured proteins which are now available to all researchers.  Every protein is expressed in E. coli, quality control tested using the relevant technology and provided in vials that contain 50µg of protein.

Examples of quality control data for a Reader, Writer and Eraser are below:

SP140 Bromodomain: Human bromodomain and PHD finger containing, 1   

Fig. 1  N-terminal 6His-tagged, recombinant, amino acids 687-862, human SP140 (1), expressed in E. coli.  Purified using immobilized metal affinity chromatography, MW = 23.6kDa. 

Bromodomain Assay:  25-1000ng of this lot of protein binf with 50nM biotin-H3 mono acetyl Lys 9.  Assay background was subtracted from the actual counts to yield the results shown below.


DOT1L: Human Disruptor of Telomeric silencing 1-like, active

Fig 2.  Human recombinant DOT1L, amino acids 1-420, expressed in E. coli.  Purified using immobilized metal affinity chromatography, MW = 47.9kDa. 

HMT Assay: 2.5-100ng of this lot of enzyme transferred methyl groups from [3H] SAM to HeLa Polynucleosome.  Assay background was substracted from the actual counts to yield the results shown below.



JMJD3:
  Human jumonji domain containing 3, active

Fig 3.  recombinant, amino acids 1141-1641, human JMJD3, expressed in E.coli. Purified using immobilised metal affinity chromatography. MW = 57.2kDa.

Demethylase Assay:  15-200ng of this lot of protein bound 200nM biotin-H3K27me3.  Assay background was subtracted from the actual counts to yield the results shown below.

×
×